AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03483987
Drug: Sof+Dacla+R+Peg-IFN arm
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
Trial: NCT03483987
Drug: Sof+Velpa+R+Peg-IFN arm
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
Trial: NCT02367755
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol use during therapeutic hypothermia
Trial: NCT02367755
Drug: Lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lorazepam use during therapeutic hypothermia
Trial: NCT03487406
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 90 mg tablet, oral, twice daily for 6 months.
Trial: NCT03487406
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 75 mg tablet, oral, once a day, for 6 months.
Trial: NCT02713802
Drug: Cudafol(R) (propofol, 1% [10 mg/mL])
RxNorm normalized name: propofol 10 MG/ML
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test product Cudafol(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes
Trial: NCT02713802
Drug: Diprivan(R) (propofol, 1% [10 mg/mL])
RxNorm normalized name: propofol 10 MG/ML [Diprivan]
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference product Diprivan(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes
Trial: NCT01132326
Drug: Droxidopa
RxNorm normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, 100, 200, 300, 400, 500, 600 mg TID, 12 months
Trial: NCT03487406
Drug: Placebo Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sugar tablet to mimic Ticagrelor 90 mg tablet. Once 90 mg tablet, oral, twice daily for 6 months.
Trial: NCT03521726
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twenty patients receive Intraluminal Amoxicillin eradication for H. pylori.
Trial: NCT03521726
Drug: Rabeprazole, Amoxicillin
RxNorm normalized name: rabeprazole, amoxicillin and metronidazole
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with high dose dual therapy (Rabeprazole, Amoxicillin) for 14 days.
Trial: NCT04504331
Drug: Infigratinib
RxNorm normalized name: INFIGRATINIB
DrugBank: Infigratinib (DB11886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dose
Trial: NCT04504331
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Dose
Trial: NCT04504331
Drug: Omnipaque 350
RxNorm normalized name: Omnipaque 350
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV contrast agent
Trial: NCT04504331
Drug: Iopamidol
RxNorm normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV contrast agent
Trial: NCT02753855
Drug: Telavancin
RxNorm normalized name: Telavancin
DrugBank: Telavancin (DB06402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of telavancin as a 1-hour intravenous infusion
Trial: NCT01732848
Drug: BMS-986094/INX-08189
DrugBank: BMS-986094 (DB11966)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01732848
Drug: Placebo matching BMS-986094/INX-08189
DrugBank: BMS-986094 (DB11966)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03319537
Drug: pevonedistat
RxNorm normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pevonedistat will be administered as an IV infusion at a dose of 50 mg/m2 days 1, 3, and 5 of a 21-day cycle.Treatment will be administered as an outpatient.
Trial: NCT03319537
Drug: Pemetrexed and cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pemetrexed, 500 mg/m2 and cisplatin, 75 mg/m2, will be given at fixed doses on day 1 of each cycle.
Trial: NCT00314314
Drug: Intranasal Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal spray; 40 IU qid; 8 weeks
Trial: NCT00314314
Drug: Diluent
RxNorm normalized name: Diluent
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal spray; 8 weeks
Trial: NCT01113502
Drug: Eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral formulation taken daily
Trial: NCT00118716
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate/salmeterol
Trial: NCT00118716
Drug: Fluticasone Propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone Propionate
Trial: NCT02284230
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01896856
Drug: SGI-110 Dose Escalation
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Dose level 1 (DL1): 45 mg/m\^2 administered as a subcutaneous injection~* Dose level 1G (DL1G): 45 mg/m\^2 administered as a subcutaneous injection + growth factor support~* Dose level -1 (DL-1): 30 mg/m\^2 administered as a subcutaneous injection~* Dose level -1G (DL-1G): 30 mg/m\^2 administered as a subcutaneous injection + growth factor support
Trial: NCT01896856
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 160 mg taken orally
Trial: NCT01896856
Drug: TAS-102
RxNorm normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg/m\^2 taken orally
Trial: NCT01896856
Drug: SGI-110
RxNorm normalized name: SGI-1776
DrugBank: SGI-1776 (DB12494)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg/m\^2 administered as a subcutaneous injection
Trial: NCT01896856
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 125 mg/m\^2 administered IV
Trial: NCT02964416
Drug: Injection Tramadol
RxNorm normalized name: tramadol Injectable Solution
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00255879
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00255879
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00255879
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00023153
Drug: Adefovir Dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00003260
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003260
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00781391
Drug: warfarin tablets
RxNorm normalized name: warfarin Oral Tablet
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin tablets plus Edoxaban placebo tablets each taken once daily for 24 months
Trial: NCT00781391
Drug: Edoxaban tablets (high dose regimen-60mg)
RxNorm normalized name: edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
Trial: NCT00781391
Drug: Edoxaban tablets (low dose regimen-30mg)
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
Trial: NCT00781391
Drug: placebo warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: placebo warfarin
Trial: NCT00781391
Drug: placebo edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: placebo edoxaban
Trial: NCT02255357
Drug: Intranasal Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: solution containing Oxytocin 6 IU/0.1cc or per puff is used in this arm
Trial: NCT00763958
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine provided for 3 months; dosing was as clinically indicated up to 32 mg daily.
Trial: NCT03043001
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All the subjects will receive add-on memantine for 12 week
Trial: NCT03802123
Drug: ⁸⁹Zr-Df-IAB22M2C
RxNorm normalized name: Zirconium zr 89-df-iab22m2c
DrugBank: Zirconium (89Zr) crefmirlimab berdoxam (DB19157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ⁸⁹Zr-Df-IAB22M2C CD8 T cell tracer for Positron Emission Tomography (PET)
Trial: NCT01822587
Drug: Propranolol, 40 mg
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00645164
Drug: Xenaderm
RxNorm normalized name: Xenaderm
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg under Finn chambers
Trial: NCT03879746
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drug will be used in treatment of premature ejaculation
Trial: NCT03879746
Drug: Paroxetine Hydrochloride
RxNorm normalized name: Paroxetine Hydrochloride
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drug will be used in treatment of premature ejaculation
Trial: NCT01323400
Drug: Pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pazopanib is administered orally at 800 mg/day (one dose every morning). A dose modification is possible in case of documented toxicity, according to specific algorithms.
Trial: NCT04225533
Drug: SP16
RxNorm normalized name: Sulfapyridine
DrugBank: Sulfapyridine (DB00891)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive a single dose of SP16
Trial: NCT03911648
Drug: 0.5 ml.kg-1 bupivacaine 0.25%
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caudally
Trial: NCT03911648
Drug: 0.5 ml.kg-1 bupivacaine 0.25% with the addition of 3 mg/kg lidocaine 1%
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caudally
Trial: NCT02240433
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib administered orally
Trial: NCT00708916
Drug: CC-10004
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment
Trial: NCT00777374
Drug: Patch
RxNorm normalized name: Patch
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epicutaneous application of allergen patch
Trial: NCT01238055
Drug: Docetaxel + Sunitinib
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 60 mg/m2 iv, every 3 weeks~Sunitinib 37.5 mg qd daily, every 3 weeks
Trial: NCT01238055
Drug: Docetaxel only
RxNorm normalized name: Docetaxel only product
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 60 mg/m2 iv
Trial: NCT03611348
Drug: Latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months.~* To apply latanoprost solution, one drop of the solution will be distributed over 1cm2 of depigmented skin. Side effects will be recorded.
Trial: NCT03509740
Drug: tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg tramadol in 100 ml saline with slow infusion
Trial: NCT03509740
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous 1 gm paracetamol in 100 ml saline with slow infusion
Trial: NCT03118024
Drug: Crystalloid Solutions
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: crystalloid restrictive anesthesia protocol
Trial: NCT04540874
Drug: BI 894416
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 894416
Trial: NCT00303199
Drug: ZIO-101 (Darinaparsin)
RxNorm normalized name: Zioptan
DrugBank: Tafluprost (DB08819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV zio-101 (Darinaparsin) give for 5 consecutive days to be repeated every 28 days for up to 6 months
Trial: NCT03701984
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).
Trial: NCT03701984
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.
Trial: NCT00353587
Drug: MBX-102
RxNorm normalized name: MBX-2109
DrugBank: MBX-2109 (DB18658)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBX-102 200 mg once daily for 16 weeks
Trial: NCT00353587
Drug: MBX-102
RxNorm normalized name: MBX-2109
DrugBank: MBX-2109 (DB18658)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBX-102 400 mg once daily for 16 weeks
Trial: NCT00353587
Drug: MBX-102
RxNorm normalized name: MBX-2109
DrugBank: MBX-2109 (DB18658)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBX-102 600 mg once daily for 16 weeks
Trial: NCT00353587
Drug: Actos
RxNorm normalized name: Actos
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Actos 30 mg once daily for 16 weeks
Trial: NCT00975910
Drug: lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine arm: lidocaine (2%) as an intravenous bolus (1.5 mg/kg) during induction followed by an intravenous infusion (2 mg. kg(-1).h(-1)) after induction until at the end of surgery
Trial: NCT00975910
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline arm: infused at the same rate as lidocaine
Trial: NCT04132843
Drug: Gadobenate Dimeglumine
RxNorm normalized name: Gadobenate Dimeglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04132843
Drug: Gadobutrol
RxNorm normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00609011
Drug: MPC-6827 + Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Temozolomide at 85 mg/m2 administered orally daily for 21 days in a 4 week cycle.
Trial: NCT00881179
Drug: Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)
RxNorm normalized name: clarithromycin Oral Tablet [Biaxin]
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01552590
Drug: Tolvaptan
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04213937
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: nab-paclitaxel 125mg/m2, i.v. d1, d8, Repeated every 3 weeks for 4-6 cycles.
Trial: NCT04213937
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Topotecan 1.25mg/m2/d, i.v, 1hour, d1-d5, Repeated every 3 weeks for 4-6 cycles.
Trial: NCT00734630
Drug: nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Encapsulated Nebivolol 5mg, 10mg, 20mg, or 40mg total daily dosage, oral administration once daily~Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration
Trial: NCT02609165
Drug: vehicle eye drops
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01408355
Drug: PF-06273588
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous, 50 microgram, single dose
Trial: NCT01408355
Drug: PF-06273588
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, 50 microgram, single dose
Trial: NCT01258634
Drug: Dexrazoxane
RxNorm normalized name: Dexrazoxane
DrugBank: Dexrazoxane (DB00380)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative Chemotherapy Courses 1, 2, 3, 4: 750mg/m2; IV over 15 minutes on day 1~Postoperative Chemotherapy for Good Responders Courses 1 and 2: 750mg/m2 IV over 15 minutes on Day 1~Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 750mg/m2 IV over 15 minutes on Day 1
Trial: NCT00929045
Drug: Growth Hormone Replacement
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01258634
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative Chemotherapy Courses 1 and 3: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol~Postoperative Chemotherapy for Good Responders Courses 1 and 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol~Postoperative Chemotherapy for Poor Responders:~Course 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol
Trial: NCT01258634
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Preoperative Chemotherapy Courses 1, 2, 3, and 4: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC \>10,000~Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC \>10,000~Postoperative Chemotherapy for Poor Responders Courses 2, 4, and 5: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC \>10,000
Trial: NCT01258634
Drug: PEG-filgrastim
RxNorm normalized name: peg-filgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Preoperative Chemotherapy Courses 1, 2, 3, and 4: 6mg; SQ starting 24 hours after chemotherapy~Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 6mg; SQ starting 24 hours after chemotherapy~Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 6mg; SQ starting 24 hours after chemotherapy
Trial: NCT01258634
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preoperative Chemotherapy Courses 2 and 4: 50mg/m2 on days 1, 2, 3, 4~Postoperative Chemotherapy for Good Responders Course 2: 50mg/m2 on days 1, 2, 3, 4 Course 3: 50mg/m2 on days, 1, 2, 3, 4 Hour 0-1~Postoperative Chemotherapy for Poor Responders Course 4: 50mg/m2 on days 1, 2, 3, 4 Course 5: 50mg/m2 on days 1, 2, 3, 4
Trial: NCT01258634
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative Chemotherapy Courses 2 and 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4~Postoperative Chemotherapy for Good Responders Course 2: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 3: 3g/m2; IV over 1 hour Days 1, 2, 3, 4~Postoperative Chemotherapy for Poor Responders Course 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 5: 3g/m2; IV over 1 hour Days 1, 2, 3, 4